Discussions on increasing coverage for atopic dermatitis treatments continue.

According to industry sources, the authorities have completed collecting expert opinions on Lilly’s JAK inhibitor ‘Olumiant (baricitinib)’ Sanofi’s ‘Dupixent (dupilumab)’ and is awaiting deliberation by the Health Insurance Review and Assessment Service’s Insurance Benefit Standard Subcommittee. The progress comes 5 months after the company submitted its application in May.

Discussions for another JAK inhibitor, Dupixent, had also started in earnest 7 months after its application. In this context, whether the addition of Olumiant will spur discussions on expanding coverage in atopic dermatitis remains t